Summary
In a double-blind cross-over study bepridil 900 mg followed by 300 mg daily for 11 days was given to 37 insulin (Type I) or non-insulin (Type II)-dependent diabetic patients.
It did not modify the metabolic control of the patients as levels of glucose in blood and urine, doses of insulin and oral hypoglycaemic drugs, energy intake, and the number of hypoglycaemic attacks during therapy were unchanged.
The serum concentration of C-peptide was not modified in either type of diabetic patient, and serum insulin in the Type I but not in the Type II patients was slightly higher during active drug treatment.
No adverse organotoxic or arrhythmogenic effects or changes in possible atherogenic lipid fractions in serum could be demonstrated during bepridil therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Malaisse WJ (1973) Insulin secretion; multifactorial regulation for a single process of release. Diabetologia 9: 167–173
Lebrun P, Malaisse WJ, Herchuelz A (1982) Evidence of two distinct modalities of Ca2+-influx into pancratic B cells. Am J Physiol 242: E59-E66
Malaisse WJ, Devis G, Pipeleers DG, Somers G (1976) Calcium antagonists and islet function. IV. Effect of D 600. Diabetologia 12: 77–81
Malaisse WJ, Sener A (1981) Calcium antagonists and islet function XII. Comparison between Nifedipine and chemically related drugs. Biochem. Pharmacol 30: 1039–1041
Charles S, Ketelslegers JM, Buysschaert M, Lambert AE (1981) Hyperglycaemic effect of nifedipine. Br Med J 283: 19–20
Giugliano D, Torella R, Cacciapuoti F, Gentile S, Verza M, Varrichio M (1980) Impairment of insulin secretion in man by nifedipine. Eur J Clin Pharmacol 18: 395–398
Donelly T, Harrower ADB (1980) Effect of nifedipine on glucose tolerance and insulin secretion in diabetic and non-diabetic patients. Curr Med Res Opin 6: 690–693
Kanatsuna T, Nakano K, Mori M, Kano Y, Nishioka M, Kajiyama S, Kitagawa Y, Yoshida T, Kondo M, Nakamura N, Aochi O (1985) Effects of nifedipine on insulin secretion and glucose metabolism in rats and in hypertensive Type 2 (non-insulin dependent) diabetics. Arzneimittelforsch 35: 514–517
Semple CG, Thomson JA, Beastall GH, Levimer AR (1983) Oral verapamil does not affect glucose tolerance in non-diabetics. J Clin Pharmacol 15: 570
Andersson DEH, Røjdmark S (1981) Improvement of glucose tolerance by verapamil, in patients with non-insulin-dependent diabetes mellitus. Acta Med Scand 210: 27–33
Chamoon H, Baylor P, Kambosos D, Charlap S, Plawes S, Frishman WH (1985) Influence of oral verapamil on glucoregulatory hormones in man. J Clin Endocrinol Metabol 60: 536–541
Segrestaa JM, Caulin C, Dahan R, Houlbert D, Thiercelin JF, Herman P, Sauvanet JP, Larnibaud J (1984) Effect of diltiazem on plasma glucose, insulin and glucagon during an oral glucose tolerance test in healthy volunteers. Eur J Clin Pharmacol 26: 481–483
Marshall RU, Winslow E, Lamar JC, Apoil E (1984) Bepridil — New drugs annual. In: Scriabine A (ed) Cardiovascular drugs, vol 2. Raven Press, New York, pp 157–176
Apoil E, Schonbaum E (1985) The clinical application of bepridil. In: van Zwieten DA, Schonbaum E (eds) Progress in pharmacology, vol 5/4. Gustav Fischer, Stuttgart New York, pp 153–165
Courtois H, Vuillermet P (1980) Action sur l'equilibre glycémique d'un nouvel antigoreux, le bépridil. Vie Med 61: 1031
Remme WJ, Kruijssen HACM, Krauss XH, van Hoogen-Huyze DCA, Storm CJ (1983) The acute haemodynamic effects of intravenous bepridil in patients with coronary heart disease. Rev Med 24: 1281–1288
Leclercq JF, Kural S, Valere PE (1983) Bepridil and Torsades de pointes. Arch Mal Coeur Vaiss 76: 341–348
Flammang D, Waynberger M, Jansen FH, Paillet R, Coumel PH (1983) Electrophysiological profile of bepridil, a new anti-anginal drug with calcium blocking properties. Eur Heart J 4: 647–654
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Husted, S.E., Pedersen, C., Nielsen, H.K. et al. Effect of bepridil on metabolic control and insulin secretion in diabetics. Eur J Clin Pharmacol 34, 221–226 (1988). https://doi.org/10.1007/BF00540947
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00540947